# Depo-Provera and Other Hormonal Contraceptives Linked to Brain Tumor Risk
A new study connects hormonal contraceptive use to increased brain tumor risk, raising questions for millions of women relying on these methods for birth control.
Researchers found that women using Depo-Provera, a progestin-only injection given every three months, faced higher rates of meningioma, a common but usually benign brain tumor. The same association appeared with other hormonal contraceptives, including combined oral pills containing estrogen and progestin.
The study examined thousands of women and tracked their contraceptive use over time. Those currently taking hormonal contraceptives showed approximately double the risk of meningioma compared to women who never used these methods. Risk decreased after stopping use, but some elevation persisted for years.
Meningioma develops in the membrane surrounding the brain and spinal cord. Most cases grow slowly and remain non-cancerous. Symptoms may include headaches, vision problems, or hearing loss, depending on tumor size and location.
The absolute risk remains low. Experts estimate roughly 2 to 3 cases per 100,000 women yearly among hormone users, compared to 1 to 2 cases in non-users. For many women, the benefits of reliable contraception outweigh this modest increased risk.
Gynecologists recommend discussing personal and family medical history with your doctor before starting hormonal contraception. Women with existing brain tumors, a family history of meningioma, or other risk factors may need alternative birth control methods. Non-hormonal options like copper IUDs, barrier methods, and permanent sterilization remain available.
This research doesn't mean women should immediately stop their contraception. Instead, use it as a conversation starter with your healthcare provider. Together, you can we